Brussels, Belgium

The International Diabetes Federation is a worldwide alliance of over 230 national diabetes associations in more than 160 countries, who have come together to enhance the lives of people with diabetes everywhere. The Federation is committed to raising global awareness of diabetes, promoting appropriate diabetes care and prevention, and encouraging activities towards finding a cure for the different types of diabetes. The Federation has been leading the global diabetes community since 1950. It is headquartered in Brussels, Belgium.IDF is divided into seven regions, with the aim of strengthening the work of national diabetes associations and enhancing the collaboration between them. IDF’s national diabetes associations are divided into the following regions: Africa ,Europe ,Middle East and North Africa , North America and Caribbean ,South and Central America , South East Asia and Western Pacific .IDF’s working bodies bring together the most important stakeholders from the global diabetes community in a collaborative effort to set common goals and co-ordinate activities towards the attainment of these goals. These stakeholders include: people with diabetes and their families; professionals involved in diabetes healthcare and related fields; diabetes representative organizations, and partners from commercial organizations with concerns which align with the mission of the Federation. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization and the Pan American Health Organization.According to the latest IDF figures, there are currently 382 million people living with diabetes and the total is expected to rise to 592 million by 2035. Some 80% of people with diabetes live in low- and middle-income countries and almost half of people living with diabetes are undiagnosed. Wikipedia.


Time filter

Source Type

- One Drop anuncia su asociación con The National Health Insurance Company – Daman, la aseguradora de salud especializada principal de los EAU y la implementación de la plataforma empresarial One Drop | Professional La compañía anuncia su asociación con The National Health Insurance Company – Daman, aseguradora de salud especializada principal de los EAU, haciendo que el cuidado completo de la diabetes esté disponible para más de 3 millones de miembros en los EAU por medio de la plataforma empresarial One Drop | Professional. NUEVA YORK, 16 de diciembre de 2016 /PRNewswire/ -- One Drop anunció hoy que The National Health Insurance Company – Daman ("Daman"), la aseguradora de salud mayor y más innovadora de los EAU, ha seleccionado One Drop para poner en marcha sus esfuerzos digitales y móviles de innovación para la salud contra la diabetes. Daman ha implementado la solución empresarial One Drop | Professional, de One Drop, para otorgar poder a sus miembros que padecen de diabetes de cara a que puedan vigilar y cuidar su salud por medio de una tecnología accesible y sencilla de utilizar. One Drop | Professional es una plataforma de gestión de la salud de la población que impulsa las interacciones en tiempo real entre personas con diabetes y sus equipos dedicados al cuidado de la salud. Con One Drop | Professional, los miembros siguen sus datos de salud y reciben formación personalizada sobre la salud por medio de la plataforma One Drop | Mobile. Los suministradores del cuidado médico pueden ver los datos de salud de los miembros en tiempo real y proporcionar la formación destacada y ampliamente personalizada, con el apoyo del contexto de la vida del día a día, que es cuando más se necesitan estas interacciones. "Estamos comprometidos de cara al uso de la tecnología más innovadora para aumentar la calidad y la eficacia del cuidado médico, y por medio de nuestra asociación con One Drop esperamos dar grandes pasos de cara al avance en el control de la diabetes y sus resultados", afirmó el doctor Michael Bitzer, consejero delegado de Daman. "La plataforma de One Drop ofrece una forma de rellenar el vacío existente entre las visitas a la clínica, y permite seguir con el cuidado necesario para que las personas con diabetes sigan estando sanas". One Drop | Professional ha sido adaptado para Daman basándose en un conocimiento completo de los hábitos sociales, estilos de vida y la cultura de las personas de los EAU. La experiencia de One Drop | Mobile se ha mejorado para incluir características especiales para los miembros de Daman, incluyendo el apoyo en idioma árabe, datos de comidas específicas de cada región, un plan de lecciones de 9 semanas de duración y un contenido organizado a través de la señal de noticias de la aplicación. Los miembros de Daman también disponen de acceso a funciones premium con las que pueden comunicarse con formadores de salud de Daman para conseguir la información y el apoyo necesarios para un mejor control de la glucosa en la sangre. En las últimas décadas, el rápido crecimiento económico de Oriente Medio ha llevado a un cambio rápido del estilo de vida y al aumento relacionado de las tasas de diabetes en la región. En la actualidad, Oriente Medio y el norte de África (MENA) cuentan con la prevalencia de diabetes más alta del mundo, con cerca de 35 millones de personas (1 de cada 10) diagnosticadas. Según la International Diabetes Federation, el 19,3% de los adultos de entre los 20 y 79 años de edad de Emiratos Árabes Unidos padecen diabetes, una enfermedad que está entre las principales causas de muerte prematura. El gasto en el tratamiento de la diabetes en la región MENA se estima subirá de 16.800 millones de dólares en 2014 a 24.700 millones de dólares en 2035, lo que supone una amenaza que afectará la economía y supondrá una bancarrota de los sistemas de cuidado de la salud. Los gobiernos y los proveedores de cuidado de la salud reconocen la gravedad de la epidemia, y desde el año 2009, el Gobierno de los EAU puso en marcha un plan de diez años para luchar contra la enfermedad, incluyendo un aumento de las investigaciones sobre la diabetes, campañas de concientización para las personas, y actualización de las instalaciones médicas. Daman está tomando un enfoque innovador usando tecnología móvil para ir más allá del cuidado de la clínica y pasarlo a la vida del día a día de la gente. One Drop | Professional combina el uso de datos en tiempo real y apoyo humano para otorgar poder a la gente y que esta pueda tomar el control de la diabetes de una forma motivadora, esperanzada y duradera. Los miembros de Daman son capaces de ver la relación entre sus conductas y el nivel de azúcar en la sangre cada día, y gracias al apoyo continuado de su formador, efectúan un cambio de conducta positivo y evitan además las complicaciones a largo plazo. "Daman es un socio ideal para implementar One Drop | Professional, ya que tienen su objetivo puesto en ofrecer a los miembros opciones inteligentes y el nivel de apoyo, confort y comodidad más alto posible en relación al cuidado de la salud", explicó Jeff Dachis, fundador y consejero delegado de One Drop. "Los EAU están entre los países que se enfrentan a las tasas de diabetes más elevadas de todo el mundo. Nuestra meta colectiva es proporcionar un cuidado asequible, accesible y eficaz basado en las evidencias de cara a la mejora de los resultados en las personas que más lo necesitan". Acerca de The National Health Insurance Company – Daman The National Health Insurance Company – Daman  es la aseguradora de salud especializada líder de los EAU, y proporciona  soluciones de seguros de salud completas para más de 3 millones de miembros en los EAU. Con los años, la compañía ha sido el socio seleccionado por varias de las organizaciones más destacadas del país y compañías multinacionales en diversos sectores, incluyendo el de petróleo y gas, aeroespacial, energía, construcción, inversiones y medios. Daman es una compañía pública de acciones conjuntas, con un 80% siendo propiedad del Gobierno de Abu Dhabi, y el restante 20% siendo propiedad de Munich Re. La compañía cuenta con el apoyo fiable del Gobierno de Abu Dhabi y su socio estratégico, Munich Re, una de las mayores reaseguradoras del mundo, dispone de un papel importante como reaseguradora y fuente valiosa para la transferencia de conocimiento. Daman, con sede central sita en Abu Dhabi y establecida en el año 2006, proporciona una serie de planes de seguro de salud a personas y a organizaciones, administrando de forma exclusiva el programa de salud del gobierno, Thiqa, para ciudadanos de EAU y el Abu Dhabi Basic Plan para expatriados de bajos ingresos. Los miembros cuentan con el acceso a la mayor red de proveedores de cuidado de salud de los EAU y a una amplia red de nivel internacional en más de 45 países. Daman, pionero en los seguros de cuidado de la salud, impulsa la innovación a través de una combinación de tecnología avanzada y experiencia dentro de la salud, ofrecida por una fuerza laboral ampliamente cualificada y conocedora. Los miembros se benefician del valor añadido por medio de las ofertas únicas, como los programas de gestión de enfermedad y casos como parte de los destacados servicios de apoyo para la salud. Daman también opera un centro telefónico de atención al cliente las 24 horas y los 7 días de la semana, disponiendo además de un equipo de autorización de servicios médicos en contacto directo con la red de proveedores de cuidado de la salud de Daman. Ofrece además una serie diversa de servicios en línea sin precedentes en los EAU. Daman ha establecido normas elevadas en la industria de los seguros de salud, recibiendo varios premios reconocidos internacionalmente y certificaciones centradas en la calidad en un período de tiempo relativamente corto. La compañía dispone del certificado ISO 9001 por Quality Management Systems. Acerca de One Drop One Drop (Informed Data Systems Inc.) es una compañía digital de salud que aprovecha la potencia de la computación móvil y la ciencia de los datos con el fin de hacer más sencillo poder otorgar poder a las personas con diabetes para que puedan disfrutar de vidas más saludables. La solución One Drop | Mobile está disponible de forma gratuita en todo el mundo a través de iOS y Android. One Drop | Premium es un servicio ofrecido por suscripción del consumidor y se puede comprar en la aplicación y de forma online en http://onedrop.today. One Drop | Professional es una solución empresarial para aseguradoras, redes de proveedores de atención médica y empleados asegurados por cuenta propia para reducir de forma importante el coste de la atención para las personas con diabetes. Para más información, visite la página web http://onedrop.today/professional.


Company announces partnership with The National Health Insurance Company – Daman, the UAE's leading specialized health insurer, making comprehensive diabetes care available to more than 3 million members in the UAE via the One Drop | Professional enterprise platform. NEW YORK, Dec. 15, 2016 /PRNewswire/ -- One Drop today announced that The National Health Insurance Company – Daman ("Daman"), the UAE's largest and most innovative health insurer, has chosen One Drop to lead its digital and mobile health innovation efforts in diabetes. One Drop's enterprise solution, One Drop | Professional, has been implemented by Daman to empower its members living with diabetes to monitor and take charge of their health through easy-to-use, accessible technology. One Drop | Professional is a population health management platform that fosters real-time interactions between people with diabetes and their healthcare teams. With One Drop | Professional, members track their health data and receive personalized health coaching through the One Drop | Mobile platform. Care providers are able to view members' health data in real-time and provide relevant, highly personalized education and support in the context of everyday life, which is when these interactions are needed most. "We are committed to using the most innovative technology to expand quality and effectiveness of care, and through our partnership with One Drop we expect to make great strides in diabetes management and outcomes," said Dr. Michael Bitzer, Chief Executive Officer at Daman. "One Drop's platform offers a way to fill the gap between clinic visits, allowing for the continuity of care necessary for people with diabetes to get and stay healthy." One Drop | Professional has been adapted for Daman based on a thorough understanding of the social habits, lifestyles and culture of the people of the UAE. The One Drop | Mobile experience has been enhanced to include special features for Daman members, including Arabic language support, region-specific food data, a 9-week lesson plan, and curated content via the in-app news feed. Daman members also have access to premium features that allow them to communicate with Daman health coaches to get the information and support needed for improved blood glucose management. Over the past few decades, rapid economic growth across the Middle East has led to a rapid change of lifestyle and a corresponding increase in the rates of diabetes in the region. Today, the Middle East and North Africa (MENA) have the highest prevalence of diabetes in the world, with nearly 35 million people (1 in every 10) diagnosed. According to the International Diabetes Federation, 19.3 percent of adults ages 20 to 79 in the United Arab Emirates have diabetes, and it is among of the leading causes of premature death. Spending on diabetes care in the MENA region is estimated to rise from $16.8  billion in 2014 to $24.7 billion in 2035, threatening to impact economics and bankrupt healthcare systems. Governments and healthcare providers have recognized the severity of epidemic and, beginning in 2009, the UAE government rolled out a ten-year plan to fight the disease including increased diabetes research, public awareness campaigns, and updated medical facilities. Daman is taking an innovative approach by using mobile technology to move care beyond the clinic and into people's everyday lives. One Drop | Professional combines the use of real-time data and human support to empower people to take ownership of their diabetes management in a way that is motivating, encouraging, and long-lasting. Daman members are able to see the relationship between their behaviors and blood sugars each day and, with the continuous support of their coach, effect positive behavioral change and avoid long-term complications. "Daman is an ideal partner for implementing One Drop | Professional, given its focus on providing members with smart choices and the highest possible level of support, comfort and convenience when it comes to healthcare." said Jeff Dachis, Founder and Chief Executive Officer of One Drop. "The UAE is among the countries facing the highest diabetes rates in the world. Our collective goal is to provide affordable, accessible, and effective evidence-based care to improve outcomes for the people who need it most." About The National Health Insurance Company – Daman The National Health Insurance Company – Daman  is the UAE's leading specialized health insurer, providing comprehensive health insurance solutions to more than 3 million members in the UAE. Over the years, the company has been the partner of choice for a number of the country's most prominent organizations and multinational companies in various industries including oil and gas, aerospace, energy, construction, investments and media. Daman is a public joint-stock company that is 80% owned by the Abu Dhabi Government with the remaining 20% owned by Munich Re. The company is backed by the reliable support of the Abu Dhabi Government and its strategic partner, Munich Re, one of the world's leading reinsurers, plays an important role as both reinsurer and a valuable source for knowledge transfer. Headquartered in Abu Dhabi and established in 2006, Daman offers a range of health insurance plans for both individuals and organizations and exclusively manages the Government's health program, Thiqa, for UAE Nationals and Abu Dhabi Basic Plan for low income expatriates. Members enjoy access to the largest healthcare providers' network in the UAE and an extensive international network of over 45 countries. Daman, a pioneer in health care insurance, drives innovation through a combination of state-of-the-art technology and healthcare-related expertise offered by a highly skilled and knowledgeable workforce. Members benefit from added value through unique offerings such as the disease and case management programs as part of the acclaimed Health Support services. Daman also operates a 24/7 customer call center and has a medical services authorization team in direct contact with Daman's network of healthcare providers. It also provides a diverse range of online services that are unmatched in the UAE. Daman has set high standards in the health insurance industry and has been awarded a number of internationally recognized awards and quality-focused certifications in a relatively short span of time. The company is ISO 9001 certified for Quality Management Systems. About One Drop One Drop (Informed Data Systems Inc.) is a digital health company harnessing the power of mobile computing and data science to empower people with diabetes to live healthier lives. The One Drop | Mobile solution is available for free worldwide on iOS and Android. One Drop | Premium is a consumer subscription service available for purchase in-app and at online at http://onedrop.today. One Drop | Professional is an enterprise solution for insurers, healthcare provider networks, and self-insured employers to dramatically lower the cost of caring for people with diabetes.  For more information, visit http://onedrop.today/professional.


HOUSTON - (March 2, 2017) - The Robert Wood Johnson Foundation (RWJF) has awarded a three-year, $2.4 million grant to The University of Texas Health Science Center at Houston (UTHealth) to create the Healthy Cities Research Hub: Exploring Drivers of Diabetes and Other Chronic Diseases. The virtual research hub will focus on the social and environmental conditions that impact health in urban settings throughout North America, facilitating knowledge exchange and evaluating community-based interventions aimed at improving public health in cities. The grant is awarded at a time when the Type 2 diabetes epidemic is threatening to overwhelm health systems. As urban populations increase, aspects of city lifestyles such as long commutes and time pressure are increasing people's vulnerability to non-communicable diseases such as Type 2 diabetes. According to the International Diabetes Federation, 415 million people across the world have diabetes, two-thirds of whom are living in urban areas. The effort represents a unique collaboration with Novo Nordisk, a global health care company, through its Cities Changing Diabetes program, which was developed in partnership with University College London and the Steno Diabetes Center to understand the social and cultural factors behind vulnerability to diabetes in urban settings and reduce its severity in cities. Cities Changing Diabetes engages a range of local partners including diabetes and health organizations, city governments, academic institutions, city experts and civil society organizations. Eight cities across the world are part of the program. The Healthy Cities Research Hub will work in three North American cities that currently have Cities Changing Diabetes programs in place: Houston, Mexico City and Vancouver. The research hub, funded by RWJF, will focus on extracting and translating the findings from these community-led efforts and sharing the results to help other cities put them into action. This includes developing a framework that evaluates social and cultural factors of health in urban settings, driving action-oriented research, developing activities between researchers and local stakeholders to convert research into new activities and producing toolkits and good practices to inspire other cities. "This is an opportunity to extend the community-based work of the Cities Changing Diabetes initiative through new tools for evaluation and dissemination so that the results proven here can help other cities," said Stephen Linder, Ph.D., lead researcher of the project and director of the Institute for Health Policy at UTHealth School of Public Health. Linder has served as the lead researcher for Cities Changing Diabetes in Houston since the program began locally in 2014. As part of the new grant, he will also work with Cities Changing Diabetes lead researchers in Mexico City and Vancouver to foster collaboration and the exchange of knowledge, experience and insight across the three cities. "We're excited to draw out specific lessons from Cities Changing Diabetes' global work to inform our efforts to transform United States cities into places that enable everyone in our diverse society to lead healthier lives now and for generations to come," said Alonzo Plough, Ph.D., vice president of Research-Evaluation-Learning and chief science officer at the Robert Wood Johnson Foundation. "When we initiated Cities Changing Diabetes, our goal was to join forces with cities and community stakeholders to understand and address the urban diabetes challenge -- globally and locally," said Niels Lund, vice president of Health Advocacy at Novo Nordisk. "This collaboration with the Robert Wood Johnson Foundation and UTHealth is an important step forward in this effort and we are proud and honored to be part of it." The grant will also allow researchers to further develop Houston's adaptation of the Cities Changing Diabetes model, which could serve as a blueprint to inspire future cities and communities involved in the program. Co-investigators from UTHealth School of Public Health include Rebecca Wells, Ph.D., Dritana Marko, M.D., Jessica Tullar, Ph.D., and Ellen Breckenridge, Ph.D., J.D.


News Article | October 29, 2016
Site: marketersmedia.com

— JumFit, a startup in the field of corporate wellness and employee engagement in the United Arab Emirates redefines corporate wellness services with the aid of big data analytics and artificial intelligence. In collaboration with a number of partners such as clinics, health clubs, trainers, dietitians and many others, the team delivers the most comprehensive employee engagement and wellness platform in the UAE. As the partners are integrated well into the program, organizations can avail the services of each provider without having to manage them separately. JumFit’s wellness solution suite focuses not only on implementing a holistic wellness program tailored to an organization’s needs but also on continually analyzing the results so as to improve the effectiveness of the program. 2. Helping individuals benefit from the incentives provided by their companies. 4. Providing organizations with analytics that is vital to measuring the Return on Employee Investment through corporate wellness programs. 5. Integrating many solution providers into a single platform and giving organizations the opportunity to make choices based on their budgets, needs and the type of corporate culture they would like to drive. JumFit’s corporate wellness AI powered platform aims to bring all this and more under its umbrella so that organizations can truly manage and administer every option available year round without taking the stress of engaging with different service providers. With the help of this platform, organizations will be able to access macro data (without compromising individual privacy) regarding health issues and engagement rates within the company. This will then help them chart a course of action to take towards re-engaging their employees and encouraging them towards adopting a healthier lifestyle. With the increasing number of heart diseases, numerous cases of hypertension, diabetes and high obesity rates among adults, employee wellness has become a vital issue in today’s world, especially in the UAE. According to the data published by the International Diabetes Federation in November 2014, 1 in 5 people in the UAE are diabetic, with 60% of the population being obese. Smoking, obesity and bad lifestyle habits cause cardiovascular diseases, hypertension and heart attacks; with cardiovascular disease being the leading cause of death worldwide today. Hypertension and high blood pressure affects one in three people globally, but in most cases it might go undetected for many years due to the lack of visible symptoms. Diabetes can also go hidden for years. Being overweight at a young age can lead to diabetes years later. Early detection and awareness, healthy food, cessation of smoking, regular exercises and other lifestyle changes can help combat the risks associated with these diseases. Employers can contribute a lot towards this through wellness programs at the workplace. This is very important as healthy people usually work more productively and are more engaged as compared to those who have health issues. Poor staff management and communication can also be the reason behind employee disengagement. A study by Gallup conducted three years ago, estimates that 74% of the workforce in the UAE is disengaged at work. The less motivated the employees are, the lower their performance levels are likely to be. Salary hikes or financial incentives alone cannot solve the problem of employee disengagement. Companies should rethink the way they manage and treat their employees so that they feel rewarded and taken care of. This does not merely involve implementing a health and fitness program. Ensuring employee wellness and engagement should be a continuous process. Each step the company takes towards achieving it should be carefully evaluated and analyzed for its effectiveness. It is this goal that JumFit helps its corporate customers achieve. JumFit provides a holistic solution that can be evaluated from time to time with the aid of modern technology. Backed by machine learning and artificial intelligence, JumFit’s wellness solution makes sure that every company it caters to, gets its own tailor made program which is frequently evaluated and improved as per its changing demands, obtained results and feedback. Soon after the launch of JumFit corporate wellness platform, the team will be launching the JumFit app. Both the platform and the app will be free of charge to organizations and app users. Also, the JumFit team will be attending the Sun & Sand Sports Fitness Fest along with their diagnostics partner, Eastern Biotech & Life Sciences. Those interested can meet them there on the 4th and 5th of November, 2016 at The Palm, Skydive Dubai. For more information, please visit https://jumfit.com


News Article | December 2, 2016
Site: www.theguardian.com

As our planet faces increasing urbanisation, public health experts are spearheading innovation for adjusting to this. We know that cities can make us ill: according to figures from the International Diabetes Federation, in 2014 there were 387 million people globally suffering from diabetes and in 2015 there were 415 million people living with the disease. Two-thirds of those people live in cities, experiencing poor diet and sedentary lifestyles. And our mental health suffers in cities, too. Urban living has been found to raise the risk of anxiety and mood disorders by 21% and 39% respectively. While half the world population currently lives in a city, this is predicted to rise to two-thirds by 2050. As they grow, cities will play a crucial role in finding solutions to many of our greatest public health challenges, from obesity and diabetes to communicable diseases like tuberculosis. With public health systems overstretched, and local governments pressed on all sides for resources and money, innovative solutions are needed. Public-private partnerships (PPPs) could be a source of new thinking, getting projects off the ground. So how can cities best build on PPPs to create health systems and fresh thinking so that our urban world will be a healthy one? How can public health bodies capitalise on the skills of the private sector without losing control? How can cities ensure equal access to healthcare for all residents? And what role should city mayors and other local government figures play in establishing innovative partnerships for health? Join an expert panel on Thursday 8 December, from 2pm to 3.30pm GMT, to discuss these questions and more. Niels Lund, vice president, Novo Nordisk and Cities Changing Diabetes spokesperson, Copenhagen, Denmark @lund_niels Cities Changing Diabetes is a programme to address the huge urban diabetes challenge. Niels has had an extensive career in international development with assignments for Unicef and the World Bank. Abdul El-Sayed, executive director and health officer, City of Detroit, United States @AbdulElSayed Abdul is turning around the fortunes of healthcare in one of America’s poorest cities, working with a variety of partners from all sectors. Laurence Carmichael, head, WHO Collaborating Centre for Healthy Urban Environments, UWE, Bristol, UK @laurencecarmich Laurence contributes to healthy cities research, consultancy and teaching in collaboration with local, national and international stakeholders including WHO-Europe. Julie Hughes, director, Institute for Market Transformation (IMT), co-director, City Energy Project, Washington DC, US The City Energy Project is a national initiative to create healthier and more prosperous American cities by improving the energy efficiency of buildings. IMT seeks market-based solutions to today’s climate and energy challenges. Susan Claris, associate director, transport consulting, Arup, London, UK, @Susan Claris Susan is a transport planner and anthropologist who has worked for Arup for more than twenty years. She has a particular interest in the many benefits that arise from making cities more walkable. Claudia Adirazola, director, Health and Road Safety, WRI Ross Center For Sustainable Cities, Washington DC, US Claudia works on a global strategy for addressing the public health impact of urban transportation and urban development. She has a background in the public sector in her home country of Peru. Tim Grandage, managing trustee, Future Hope, Kolkata, India Tim founded Future Hope, a charity that works with vulnerable children in Kolkata’s streets and slums, in 1987. Federico Cartin Arteaga, director, Rutas Naturbanas, San José, Costa Rica, @fedecartin Federico is an economist and urban planner. Rutas Naturbanas aims to revitalise urban rivers – to allow people to bike, walk and run – and eventually restore these water sheds. Alex Ross, director, World Health Organisation (WHO) Centre for Health Development (WHO Kobe Centre), Kobe, Japan, @directorwkc The WHO Kobe Centre has been working on urban health for over a decade, addressing health systems, health inequities and and urban planning-health collaboration. Alex’s background is in international development, with roles at USAid and DfID. Billie Giles-Corti, lead of the NHMRC Centre for Research Excellence in Healthy Liveable Communities, University of Melbourne, Melbourne, Australia, @billiegc Billie heads a centre with the mission to provide research that informs healthy urban design and planning. She is the author of a 2016 Lancet series on urban design, transport and health. Jess Beagley, policy research officer, NCD Alliance, London, UK, @JessicaBeagley Jess leads NCD Alliance’s work on environment and health, with a particular focus on urbanisation and climate change and the opportunities for co-benefit solutions to promote human and planetary health. The live chat is not video or audio-enabled but will take place in the comments section (below). Want to recommend someone for the panel or ask a question in advance? Get in touch via globaldevpros@theguardian.com or @GuardianGDP on Twitter. Follow the discussion using the hashtag #globaldevlive.


Sarasota, FL, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Heart Failure Software Market by Software Type (Knowledge-Based and Non-Knowledge Based) and by Delivery Mode (On-Premises, Web-Based and Cloud-Based Systems) for Hospitals and Others - Global Industry Perspective, Comprehensive Analysis and Forecast 2016 – 2022”.  According to the report, the global heart failure software market accounted for approximately USD 2.23 billion in 2016 and is expected to reach around USD 3.18 billion by 2022, growing at a CAGR of around 6.1% between 2017 and 2022. Congestive heart failure is a chronic condition that directly affects the pumping power of your heart muscles. CHF particularly refers the phase in which fluid increases around the heart and causes it force inefficiently. Rising necessity for continuous health assessment and dynamic advancements in technology is the major factor associated with heart failure software growth. In addition, clinical decision support system such as heart failure software system is continuously being used in the developed economies like the U.S., Germany, and France. Heart failure software facilitates management of cardiac patients safely and efficiently. It provides benefits patients in cardiac activity monitoring and analyzing risk zone of patients with cardiac diseases.  Browse through 42 Market Tables and 33 Figures spread through 110 Pages and in-depth TOC on “Global Heart failure software Market: By Type, Technology, Delivery Mode, Size, Share and Forecast 2016 – 2022”. Heart failure software market is driven mainly by increasing incidence of heart-related diseases across the different parts of the world. These diseases include angina pectoris, diabetes, hypertension etc. For instance, according to the International Diabetes Federation, China had the largest number of diabetic patients with around 96.2 million diabetic patients followed by India with around 66.8 million diabetic patients in 2014 which directly helped in fueling the heart failure software market. However, high costs or non-affordability of heart failure software are the key limitations which directly affects the growth of heart failure software market. Non-awareness and illiteracy among the population may directly affect the growth of heart failure software market. Advancement and innovation in technologies will boost the heart failure software market growth. Based on software type, the global market for heart failure software is classified into types: knowledge based and non-knowledge based. Global heart failure software market is dominated by knowledge-based software market. The knowledge-based software market is growing at the much faster rate in each year. The knowledge-based software will show more innovations and technological advances due to the demands by customers and medical professionals. Browse the full "Heart failure software Market by Software Type (Knowledge Based, Non-Knowledge Based,) and by Delivery mode (On-Premises, Web-Based and Cloud-Based Systems) for Hospitals and Others - Global Industry Perspective, Comprehensive Analysis and Forecast 2016 – 2022" report at https://www.zionmarketresearch.com/report/heart-failure-software-market Based on delivery mode, the global market of heart failure software market is classified into three types: on-premises, web-based and cloud-based systems. Globally, heart failure software market was dominated by cloud-based systems in 2016. This growth is attributed due to increasing prevalence of diabetes mellitus. Diabetes mellitus patient is at higher risk of heart failure followed by nondiabetes patients. This risk associated with blood viscosity, which is higher in diabetes mellitus patient. About 100,000 new cases of type 1 diabetes are diagnosed annually in North America.   Based on end-users, the global market of heart failure software market is classified into types: hospitals and others. Hospital segment dominated the end-users segment in 2016. This growth is attributed due to increasing adoption of electronic health records and remote patient monitoring system. Rising awareness about personal health amongst the population is expected to drive the growth of the consumer segment over the near future. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/heart-failure-software-market North America was the dominating region for heart failure software market in 2016. The growth was accredited to rising awareness amongst the population regarding the symptoms of heart diseases. Moreover, high-end research and technological advancements, increasing public interest are the important key factors which drive the demand of heart failure software market in this region. Higher healthcare expenditure in this region is important for the growth factors for heart failure software market. In 2014, the North American market for heart failure software was estimated more than USD 940 million and projected to reach approximately USD 1.40 billion in 2021 growing at a CAGR of around 7.0%. North America accounted for approximately more than 44% of total revenue of heart failure software market. In the European Union, there are approximately more than 31 million people living with diabetes aged between 20 and 79. This signifies an average diabetes prevalence rate of 8.6% of the adult population. This signifies the increasing market of heart failure software market in the EU. Europe was the second largest market for global heart failure software market in 2015 and it accounted for approximately USD 814.50 million in 2016. This growth is mainly associated with advancement in technological and healthcare research in this region. The Asia-Pacific region may offer significant opportunities for the heart failure software market during the forecast period. At present, China and India being the most populous countries in the region are contributing to the increase in demand for heart failure software market. China is a second largest economy after the U.S. is home to the world’s largest population with close to 1.4 billion inhabitants followed by India with approximately 1.2 billion people in 2014. Approximately 40-45% of the global heart disorder population lives in India and China which in turn provides significant opportunities for the global heart failure software companies to invest in this region. Growing cases of heart-related problem in the Middle East and Africa are also likely to fuel the growth of heart failure software market. In 2016 the Middle East and Africa accounted for approximately USD 78.50 million in terms of revenue. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global heart failure software market include Cerner Corporation, 4S Information Systems Ltd., Axis Clinical Software, Inc., CitiusTech Inc., etc.     For more inquiry contact our sales team @ sales@zionmarketresearch.com This report segments the global heart failure software market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.


According to the research report, the opportunity in the global Diabetes Injection Pens Market is expected to be worth US$9.7 bn by the end of 2024 as compared to US$4.9 bn in 2015. Between the forecast years of 2016 and 2024, the global market is projected to rise at a CAGR of 7.9%. The leading players operating in the global diabetes injection pens market are Novo Nordisk A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports that the competitive landscape in the global market is consolidated due to dominance of a few large players. "Incorporating latest technological innovations to manufacture state-of-art diabetes injection pens will remain the focus of these companies," states the lead author of this research report. Insulin Pens Show Continued Growth as Users Prefer it Over Pen Needles On the basis of product, the global market is segmented into insulin pens and pen needles. Of these, the insulin pens are anticipated to assume the lead in the global market during the forecast period. By the end of 2024, the insulin pens segment is expected to acquire a share of 64.8%. The convenience of using insulin pens as compared to syringes and pumps is expected to drive their demand in the coming years. In terms geography, the global diabetes injection pens market is segmented into North America, Europe, Asia, Latin America, and Rest of the World. Currently, North America holds a dominating share in the global market due to a high degree of awareness about diabetes and its management. Asia Pacific is projected to grow at a steady rate during the forecast period due to a vast pool of patients that are expected to present a score of opportunities. Poor lifestyle choices and lack of time to exercise are precursors to the life-altering disease known as diabetes. Genetic predisposition and side-effect of other ailments are also to cause diabetes. Statistics presented by the American Diabetes Association state that about 71,000 die each year due to diabetic complications across the U.S. On a similar note, the International Diabetes Federation stated that there were 415 million diabetics across the world in 2015 and the number is estimated to rise by 10% by 2040. These unfortunate figures indicate a high prevalence of diabetes across the world, which is expected to be the primary growth driver for the growth of the global diabetes injection pens market. The demand for diabetes injection pens is also expected to be fueled by the increasing cases of needle stick injuries. Usage of needles can lead to percutaneous piercing wounds due to incorrect handling, disassembling, or disposing. Owing to this, several healthcare professionals are promoting the usage of injection pens for administering insulin. Design and development of diabetes injection pens that are safe, easy to use, cost-effective, and relatively pain-free are also likely to encourage type 1 diabetics to use them. The steady market growth will waver due to the growing number of substitutes in the market. The introduction of a wide range of technologies that offer substitute products is likely to hamper market growth. Furthermore, the possibility of artificial pancreas and disposable insulin patches are also projected to have a negative impact on the global market in the coming years. Poor reimbursement policies for diabetes injection pens is also restraining the growth rate of the global market. This review is based on Transparency Market Research's report, titled "Diabetes Injection Pens Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2016 - 2024." The global diabetes injection pens market is segmented as follows: Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 http://www.transparencymarketresearch.com/diabetes-devices-market.html Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase II | Award Amount: 1.50M | Year: 2013

DESCRIPTION (provided by applicant): According to UnitedHealth14 by 2020 half of all Americans would have either diabetes or pre-diabetes with an annual cost of 500 billion - mainly attributed to diabetes related complications. Diabetes is a growing epidemic yet treatment goals are seldom achieved, and patients endure detrimental complications. In the US, 65% of all insulin takers (most of which have type-2 diabetes) have HbA1cgt7% and thus they are susceptible to complications. The challenge is that in reality insulin dosage is rarely titrate between clinic appointments27. Multiple studies with patients with type-2 and type-1 diabetes incorporating different insulin regimens showed frequent titration of insulin dosage is the key element to achieve therapygoal in the majority of patients2-10. Unfortunately, there is no single, patient-friendly, cost-effective, safe and effective intervention that provides frequent insulin titration to patients and maximizes the potential benefits of insulin therapy. Hygieia developed the Diabetes Insulin Guidance System (DIGS ) software (formerly called Private-Doc ) to automate the process of insulin dosage titration. The DIGS insulin adjustment software emulates the way clinicians evaluate and adjust dosage. The utilityof the DIGS software has been demonstrated in a prospective 16-week clinical trial during the Phase I STTR project12. In the Phase I study, the DIGS software titrated insulin therapy of 38 adults with type-1 and type-2 diabetes, on a weekly basis, resulting in improved glycolic control (lower HbA1c, mean glucose, and frequency of hypoglycemia). Hygieia further developed d-Nav, a handheld device, combining a glucose meter with the DIGS software that analyzes blood glucose patterns and periodically adjust theuser's insulin dosage. The goal is to have insulin takers use d-Nav instead of a glucose meter, at a similar cost and requiring no behavioral changes or increased testing frequency, leading to superior glycolic control. The d-Nav DIGS will be given to patients free of charge by their primary care physician (PCP), while the cost of consumable d-Nav glucose test strips is covered by medical insurance. In Phase II, Hygieia seeks to recruit [200] insulin treated patients in a prospective, open-label, randomized, controlled, multi-center, 6- month trial assessing the efficacy and safety of insulin therapy using d-Nav compared to a [smart] glucose meters in patients with type-2 diabetes. Upon enrollment patients will be randomized to either receive d-Nav or a [smart] glucose meter. Efficacy will be tested by attenuation in HbA1c and safety by the frequency and severity of hypoglycemia. The objectives are to establish clinical indication for registration and convince PCPs insulin therapy combined with d-Nav is safe and effective. We believe once d-Nav becomes widely available to insulin takers, optimization of insulin dosage will reduce incidence of diabetic complications and alleviate the health care system burden, thus saving billions of dollars in national health care costs. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Despite immense effort to achieve balanced glucose control, millions of insulin-treated diabetic patients have high glucose levels and develop devastating complications at tremendousannual cost. Hygieia's DIGS software - now embedded in the d-Nav device - was previously proven, in a prospective study, capable of optimizing patient's insulin dosage leading to superior glycolic control12. The proposed study will test d-Nav's ability,as a single intervention compared to a [smart] blood glucose meter, to improve glycolic control for insulin takers, establishing it as the companion primary care physicians recommend to their insulin treated patients, thus leading to improved diabetes management, and reduced complications of the disease - saving billions of tax payer dollars in health care costs.


News Article | October 31, 2016
Site: www.PR.com

JumFit, a unique UAE-based web platform and app, aims to revolutionize corporate wellness services by powering them with Artificial Intelligence. Dubai, United Arab Emirates, October 31, 2016 --( JumFit’s services include the following: 1. Helping companies analyze their wellness needs. 2. Helping individuals benefit from the incentives provided by their companies. 3. Designing programs encompassing wellness, health, engagement, gamification and team building initiatives. 4. Providing organizations with analytics that is vital to measuring the Return on Employee Investment through corporate wellness programs. 5. Integrating many solution providers into a single platform and giving organizations the opportunity to make choices based on their budgets, needs and the type of corporate culture they would like to drive. JumFit’s corporate wellness AI powered platform aims to bring all this and more under its umbrella so that organizations can truly manage and administer every option available year round without taking the stress of engaging with different service providers. With the help of this platform, organizations will be able to access macro data (without compromising individual privacy) regarding health issues and engagement rates within the company. This will then help them chart a course of action to take towards re-engaging their employees and encouraging them towards adopting a healthier lifestyle. With the increasing number of heart diseases, numerous cases of hypertension, diabetes and high obesity rates among adults, employee wellness has become a vital issue in today’s world, especially in the UAE. According to the data published by the International Diabetes Federation in November 2014, 1 in 5 people in the UAE are diabetic, with 60% of the population being obese. Smoking, obesity and bad lifestyle habits cause cardiovascular diseases, hypertension and heart attacks; with cardiovascular disease being the leading cause of death worldwide today. Hypertension and high blood pressure affects one in three people globally, but in most cases it might go undetected for many years due to the lack of visible symptoms. Diabetes can also go hidden for years. Being overweight at a young age can lead to diabetes years later. Early detection and awareness, healthy food, cessation of smoking, regular exercises and other lifestyle changes can help combat the risks associated with these diseases. Employers can contribute a lot towards this through wellness programs at the workplace. This is very important as healthy people usually work more productively and are more engaged as compared to those who have health issues. Poor staff management and communication can also be the reason behind employee disengagement. A study by Gallup conducted three years ago, estimates that 74% of the workforce in the UAE is disengaged at work. The less motivated the employees are, the lower their performance levels are likely to be. Salary hikes or financial incentives alone cannot solve the problem of employee disengagement. Companies should rethink the way they manage and treat their employees so that they feel rewarded and taken care of. This does not merely involve implementing a health and fitness program. Ensuring employee wellness and engagement should be a continuous process. Each step the company takes towards achieving it should be carefully evaluated and analyzed for its effectiveness. It is this goal that JumFit helps its corporate customers achieve. JumFit provides a holistic solution that can be evaluated from time to time with the aid of modern technology. Backed by machine learning and artificial intelligence, JumFit’s wellness solution makes sure that every company it caters to, gets its own tailor made program which is frequently evaluated and improved as per its changing demands, obtained results and feedback. Soon after the launch of JumFit corporate wellness platform, the team will be launching the JumFit app. Both the platform and the app will be free of charge to organizations and app users. Also, the JumFit team will be attending the Sun & Sand Sports Fitness Fest along with their diagnostics partner, Eastern Biotech & Life Sciences. Those interested can meet them there on the 4th and 5th of November, 2016 at The Palm, Skydive Dubai. For more information, please visit https://jumfit.com. Dubai, United Arab Emirates, October 31, 2016 --( PR.com )-- JumFit, a startup in the field of corporate wellness and employee engagement in the United Arab Emirates redefines corporate wellness services with the aid of big data analytics and artificial intelligence. In collaboration with a number of partners such as clinics, health clubs, trainers, dietitians and many others, the team delivers the most comprehensive employee engagement and wellness platform in the UAE. As the partners are integrated well into the program, organizations can avail the services of each provider without having to manage them separately. JumFit’s wellness solution suite focuses not only on implementing a holistic wellness program tailored to an organization’s needs but also on continually analyzing the results so as to improve the effectiveness of the program.JumFit’s services include the following:1. Helping companies analyze their wellness needs.2. Helping individuals benefit from the incentives provided by their companies.3. Designing programs encompassing wellness, health, engagement, gamification and team building initiatives.4. Providing organizations with analytics that is vital to measuring the Return on Employee Investment through corporate wellness programs.5. Integrating many solution providers into a single platform and giving organizations the opportunity to make choices based on their budgets, needs and the type of corporate culture they would like to drive.JumFit’s corporate wellness AI powered platform aims to bring all this and more under its umbrella so that organizations can truly manage and administer every option available year round without taking the stress of engaging with different service providers. With the help of this platform, organizations will be able to access macro data (without compromising individual privacy) regarding health issues and engagement rates within the company. This will then help them chart a course of action to take towards re-engaging their employees and encouraging them towards adopting a healthier lifestyle.With the increasing number of heart diseases, numerous cases of hypertension, diabetes and high obesity rates among adults, employee wellness has become a vital issue in today’s world, especially in the UAE. According to the data published by the International Diabetes Federation in November 2014, 1 in 5 people in the UAE are diabetic, with 60% of the population being obese. Smoking, obesity and bad lifestyle habits cause cardiovascular diseases, hypertension and heart attacks; with cardiovascular disease being the leading cause of death worldwide today. Hypertension and high blood pressure affects one in three people globally, but in most cases it might go undetected for many years due to the lack of visible symptoms. Diabetes can also go hidden for years. Being overweight at a young age can lead to diabetes years later. Early detection and awareness, healthy food, cessation of smoking, regular exercises and other lifestyle changes can help combat the risks associated with these diseases. Employers can contribute a lot towards this through wellness programs at the workplace. This is very important as healthy people usually work more productively and are more engaged as compared to those who have health issues.Poor staff management and communication can also be the reason behind employee disengagement. A study by Gallup conducted three years ago, estimates that 74% of the workforce in the UAE is disengaged at work. The less motivated the employees are, the lower their performance levels are likely to be. Salary hikes or financial incentives alone cannot solve the problem of employee disengagement. Companies should rethink the way they manage and treat their employees so that they feel rewarded and taken care of. This does not merely involve implementing a health and fitness program. Ensuring employee wellness and engagement should be a continuous process. Each step the company takes towards achieving it should be carefully evaluated and analyzed for its effectiveness. It is this goal that JumFit helps its corporate customers achieve.JumFit provides a holistic solution that can be evaluated from time to time with the aid of modern technology. Backed by machine learning and artificial intelligence, JumFit’s wellness solution makes sure that every company it caters to, gets its own tailor made program which is frequently evaluated and improved as per its changing demands, obtained results and feedback.Soon after the launch of JumFit corporate wellness platform, the team will be launching the JumFit app. Both the platform and the app will be free of charge to organizations and app users.Also, the JumFit team will be attending the Sun & Sand Sports Fitness Fest along with their diagnostics partner, Eastern Biotech & Life Sciences. Those interested can meet them there on the 4th and 5th of November, 2016 at The Palm, Skydive Dubai.For more information, please visit https://jumfit.com. Click here to view the list of recent Press Releases from Obocart FZC


News Article | December 6, 2016
Site: www.marketwired.com

BROSSARD, QUEBEC--(Marketwired - Dec. 6, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in applying Artificial Intelligence in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a pilot project contract for diabetic macular edema and diabetic retinopathy screening with BAYER Canada. Under the terms of the agreement, DIAGNOS will provide a fully turn-key screening service to benefit one thousand diabetic patients in the Toronto area. Screening will be offered to diabetics affiliated to their health entities to test the impact of including preventive screening programs. According to the International Diabetes Federation, diabetic retinopathy and macular edema are the most common diabetic eye diseases and the leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection methods critical by helping the prevention of vision loss. "The opportunity to partner with Bayer offers an immense advantage at detecting treatable diabetic retinopathy using the advanced Artificial Intelligence technology and eliminating sight-threatening complications of this disease", said Netan Choudhry, MD FRCS(C) DABO, director at DIAGNOS. Mr. André Larente, President of DIAGNOS, added "We are excited to start our new commercial relationship with BAYER in Canada and begin screening for diabetic macular edema and retinopathy. Following the expected success of this project, we intend to expand the scope of services offered through this pharmaceutical company into other countries." Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please visit our website at www.diagnos.com, or visit the SEDAR website at www.sedar.com.

Loading International Diabetes Federation collaborators
Loading International Diabetes Federation collaborators